tradingkey.logo
tradingkey.logo
Pesquisar

Veracyte Inc

VCYT
Adicionar à lista de desejos
57.080USD
-2.770-4.63%
Fechamento 07/02, 13:00ETCotações atrasadas em 15 min
4.53BValor de mercado
51.19P/L TTM

Mais detalhes de Veracyte Inc Empresa

Veracyte, Inc. is a global diagnostics company. The Company enables clinicians with insights they need to guide and help patients to diagnose and treat cancer. The Veracyte Diagnostics Platform delivers cancer tests that are fueled by broad genomic and clinical data, deep bioinformatic and AI capabilities, and an evidence-generation engine, which drives durable reimbursement and guideline inclusion for its tests, along with new insights to support continued innovation and pipeline development. The Company offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna) and bladder cancer (Decipher Bladder). It has developed the noninvasive Percepta Nasal Swab test to help physicians accurately and quickly determine lung cancer risk. All of its tests are serviced through its own Clinical Laboratory Improvement Amendments (CLIA) certified laboratories in South San Francisco, California, San Diego, California and Austin, Texas.

Informações de Veracyte Inc

Código da empresaVCYT
Nome da EmpresaVeracyte Inc
Data de listagemOct 30, 2013
CEOStapley (Marc A)
Número de funcionários824
Tipo de títulosOrdinary Share
Fim do ano fiscalOct 30
Endereço6000 Shoreline Court, Suite 300
CidadeSOUTH SAN FRANCISCO
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal94080
Telefone16502436300
Sitehttps://www.veracyte.com/
Código da empresaVCYT
Data de listagemOct 30, 2013
CEOStapley (Marc A)

Executivos da empresa Veracyte Inc

Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Marc A. Stapley
Mr. Marc A. Stapley
Chief Executive Officer, Director
Chief Executive Officer, Director
142.40K
-6.33%
Dr. Robert S. (Rob) Epstein, M.D.
Dr. Robert S. (Rob) Epstein, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
48.40K
+10.89%
Dr. Eliav Barr, M.D.
Dr. Eliav Barr, M.D.
Independent Director
Independent Director
47.14K
+11.18%
Ms. Muna Bhanji
Ms. Muna Bhanji
Independent Director
Independent Director
35.26K
+14.95%
Dr. Phillip G. (Phil) Febbo, M.D.
Dr. Phillip G. (Phil) Febbo, M.D.
Chief Scientific Officer, Chief Medical Officer
Chief Scientific Officer, Chief Medical Officer
28.33K
-13.16%
Mr. Evan Jones
Mr. Evan Jones
Independent Director
Independent Director
25.31K
+20.83%
Ms. Rebecca Chambers
Ms. Rebecca Chambers
Chief Financial Officer
Chief Financial Officer
24.86K
-29.18%
Mr. Jens Holstein
Mr. Jens Holstein
Independent Director
Independent Director
23.15K
+22.77%
Mr. John Leite, Ph.D.
Mr. John Leite, Ph.D.
Global Chief Commercial Officer
Global Chief Commercial Officer
13.76K
-29.49%
Ms. Karin Eastham, CPA
Ms. Karin Eastham, CPA
Independent Director
Independent Director
5.78K
+26.71%
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Marc A. Stapley
Mr. Marc A. Stapley
Chief Executive Officer, Director
Chief Executive Officer, Director
142.40K
-6.33%
Dr. Robert S. (Rob) Epstein, M.D.
Dr. Robert S. (Rob) Epstein, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
48.40K
+10.89%
Dr. Eliav Barr, M.D.
Dr. Eliav Barr, M.D.
Independent Director
Independent Director
47.14K
+11.18%
Ms. Muna Bhanji
Ms. Muna Bhanji
Independent Director
Independent Director
35.26K
+14.95%
Dr. Phillip G. (Phil) Febbo, M.D.
Dr. Phillip G. (Phil) Febbo, M.D.
Chief Scientific Officer, Chief Medical Officer
Chief Scientific Officer, Chief Medical Officer
28.33K
-13.16%
Mr. Evan Jones
Mr. Evan Jones
Independent Director
Independent Director
25.31K
+20.83%

Perguntas frequentes

Quem são os cinco principais acionistas de Veracyte Inc?

Os cinco principais acionistas de Veracyte Inc são: Mr. Marc A. Stapley

Quantas instituições possuem ações da Veracyte Inc (VCYT)?

Em 2026Q1, 683 instituições possuíam ações da Veracyte Inc, com valor de mercado aproximado de 96.10M, representando 120.44% do total de ações. Em comparação com 2025Q4, a participação institucional aumentou em -1894546.00.